EMF vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
EMF presents a compelling value opportunity, anchored by a stable Piotroski F-Score of 5/9 and a current price ($20.41) that sits significantly below both its Graham Number ($36.14) and Intrinsic Value ($99.12). The fund exhibits exceptional valuation metrics with a P/E of 6.07, far below the sector average, and a strong ROE of 20.84%. While revenue growth is currently negative (-13.30%), the massive surge in earnings growth (98.90%) and negligible debt (D/E 0.02) suggest high operational efficiency. Despite a bearish technical trend score, the fundamental disconnect between price and fair value provides a substantial margin of safety.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
EMF vs JPM: Head-to-Head Comparison
This page compares Templeton Emerging Markets Fund (EMF) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.